DE60229240D1 - Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes - Google Patents

Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes

Info

Publication number
DE60229240D1
DE60229240D1 DE60229240T DE60229240T DE60229240D1 DE 60229240 D1 DE60229240 D1 DE 60229240D1 DE 60229240 T DE60229240 T DE 60229240T DE 60229240 T DE60229240 T DE 60229240T DE 60229240 D1 DE60229240 D1 DE 60229240D1
Authority
DE
Germany
Prior art keywords
vitamin
treatment
autoimmune diabetes
analog
hexafluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60229240T
Other languages
English (en)
Inventor
Luciano Adorini
Nadia Giarratana
Silvia Gregori
Simona Smiroldo
Milan Radoje Uskokovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxell SpA filed Critical Bioxell SpA
Application granted granted Critical
Publication of DE60229240D1 publication Critical patent/DE60229240D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Steroid Compounds (AREA)
DE60229240T 2001-05-22 2002-05-10 Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes Expired - Fee Related DE60229240D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112421 2001-05-22
PCT/EP2002/005162 WO2002094247A2 (en) 2001-05-22 2002-05-10 Use of a vitamin d3 analogue for the treatment of autoimmune diabetes

Publications (1)

Publication Number Publication Date
DE60229240D1 true DE60229240D1 (de) 2008-11-20

Family

ID=8177502

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229240T Expired - Fee Related DE60229240D1 (de) 2001-05-22 2002-05-10 Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes

Country Status (6)

Country Link
US (1) US20040214803A1 (de)
EP (1) EP1392323B1 (de)
AT (1) ATE410172T1 (de)
AU (1) AU2002314056A1 (de)
DE (1) DE60229240D1 (de)
WO (1) WO2002094247A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
JP2007506765A (ja) * 2003-09-24 2007-03-22 ビオクセル エッセ ピ ア １，３−ジアシル化２６，２７−アルキル／ハロアルキルビタミンｄ３化合物及びその使用方法
NZ555283A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
US7241749B2 (en) * 2004-11-22 2007-07-10 Wisconsin Alumni Research Foundation 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses
US7241752B2 (en) 2004-11-22 2007-07-10 Wisconsin Alumni Research Foundation 17,20(E)-dehydro vitamin D analogs and their uses
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
WO2008125901A2 (en) 2006-04-06 2008-10-23 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
AU2007234717B2 (en) 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
AU2007298673A1 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
CN103784419B (zh) * 2012-10-31 2016-03-30 成都国弘医药有限公司 一种含有骨化三醇的软胶囊及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
JP2001503061A (ja) * 1996-10-31 2001-03-06 アメリカン・ホーム・プロダクツ・コーポレイション ラパマイシンおよびカルシトリオールを含んでなる相乗組成物
CA2303248A1 (en) * 1997-09-08 1999-03-18 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs

Also Published As

Publication number Publication date
ATE410172T1 (de) 2008-10-15
WO2002094247A3 (en) 2003-05-01
EP1392323B1 (de) 2008-10-08
EP1392323A2 (de) 2004-03-03
US20040214803A1 (en) 2004-10-28
AU2002314056A1 (en) 2002-12-03
WO2002094247A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
ATE503490T1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
ATE445405T1 (de) Vorbeugung und behandlung von oxidativer-stress- erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
DE60203847D1 (de) Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
RU2007112409A (ru) Одновременный прием тигициклина и дигоксина
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE249832T1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee